<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20140610104752+01'00'</creation_date><modification_date>D:20210531120628+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_epar-other_1.pdf</pdf_file></head><body><section><header n="20">20 march 2014 ema/chmp/322518/2014 
 committee for medicinal products for human use (chmp) 
 pegintron international non-proprietary name: peginterferon alfa-2b procedure no.  emea/h/c/000280/psuv/0117 
 period covered by the psur:  25.07.2010 to 24.07.2013</header></section><section><header>scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation</header><p>7 westferry circus ● canary wharf ● london e14 4hb ● united kingdom an agency of the european union</p><p>telephone +44 (0)20 7418 8400 facsimile +44 (0)20 7523 7455 e-mail info@ema.europa.eu website www.ema.europa.eu © european medicines agency, 2014. reproduction is authorised provided the source is acknowledged. 
 medicinal product no longer authorised</p></section><section><header>scientific conclusions</header><p>taking into account the prac assessment report on the psur for pegintron, the scientific conclusions of prac are as follows:</p><p>
 the overall benefit of pegintron in the authorised indications was not altered as a result of new 
 information that became available during the reporting period of this psur.</p><p> 
 based on a review of data concerning tongue pigmentation provided in this psur as well as similar 
 data provided in the psur of another peginterferon alfa containing product, the prac considered that 
 tongue pigmentation should be added as an adverse drug reaction to section 4.8 of the smpc and 
 that the package leaflet be updated accordingly.</p><p>
 the chmp agrees with the scientific conclusions made by the prac.</p></section><section><header>grounds recommending the variation to the terms of the marketing authorisation</header><p>on the basis of the scientific conclusions for pegintron, the chmp is of the opinion that the benefit-risk balance of the medicinal product containing the active substance peginterferon alfa-2b is favourable 
 subject to the proposed changes to the product information. 
 the chmp recommends that the terms of the marketing authorisation should be varied.</p><p> page 2</p><p> medicinal product no longer authorised</p></section></body></xml>